Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

@article{Kim2011HighlySP,
  title={Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients},
  author={P. Kim and X. Liu and T. Lee and L. Liu and R. Barham and R. Kirkland and G. Leesman and Anne Kuller and B. Ybarrondo and Shi-Chung Ng and S. Singh},
  journal={Proteome Science},
  year={2011},
  volume={9},
  pages={75 - 75}
}
  • P. Kim, X. Liu, +8 authors S. Singh
  • Published 2011
  • Medicine, Biology
  • Proteome Science
  • BackgroundThe clinical benefits associated with targeted oncology agents are generally limited to subsets of patients. Even with favorable biomarker profiles, many patients do not respond or acquire resistance. Existing technologies are ineffective for treatment monitoring as they provide only static and limited information and require substantial amounts of tissue. Therefore, there is an urgent need to develop methods that can profile potential therapeutic targets with limited clinical… CONTINUE READING
    34 Citations
    A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma
    • 4
    • PDF
    Quantification of HER family receptors in breast cancer
    • 36
    • PDF
    A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
    • 29
    • PDF
    Clinical application of circulating tumor cells in breast cancer
    • 38
    Recent Advances in the Molecular Characterization of Circulating Tumor Cells
    • 44
    • PDF
    Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.
    • 23
    • PDF

    References

    SHOWING 1-10 OF 71 REFERENCES
    HER-2 gene amplification can be acquired as breast cancer progresses.
    • S. Meng, D. Tripathy, +21 authors J. Uhr
    • Medicine, Biology
    • Proceedings of the National Academy of Sciences of the United States of America
    • 2004
    • 536
    • PDF
    Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    • 103
    Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
    • 411
    • PDF
    Current issues in ER and HER2 testing by IHC in breast cancer
    • A. Gown
    • Medicine
    • Modern Pathology
    • 2008
    • 307
    • PDF
    Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
    • 128
    Systematic Review of HER2 Breast Cancer Testing
    • 90
    Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
    • 16
    • PDF
    Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
    • 1,053
    • PDF